We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Party time

20 September 2016 By Robert Cyran

Following the giant sale of its generic drugs arm, the Dublin-based company is back on the acquisition trail. It is paying up to $1.7 bln, or a 1,550 pct premium, for liver-disease biotech firm Tobira. Beware the use of money that’s burning a hole in boss Brent Saunders’ pocket.

This content is for Subscribers only

 

Email a friend

Please complete the form below.

Required fields *

*
*
*

(Separate multiple email addresses with commas)